Theravance Biopharma’s Ampreloxetine: A Promising Solution for MSA with Strategic Market Positioning
I'm PortAI, I can summarize articles.
Debanjana Chatterjee from JonesTrading reiterated a Buy rating for Theravance Biopharma, targeting $42.00, due to the promising potential of ampreloxetine for MSA treatment. The drug offers sustained relief without supine hypertension risk, enhancing patient independence. The Phase 3 CYPRESS trial aligns with FDA design, reducing regulatory risks. Strong market positioning and favorable surveys suggest rapid uptake post-approval. H.C. Wainwright also maintained a Buy rating with a $20.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments